The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 26, 2019
Filed:
Apr. 05, 2017
Applicant:
Mindimmune Therapeutics, Inc., Kingston, RI (US);
Inventors:
John Paul Kilburn, Haslev, DK;
Lars Kyhn Rasmussen, Vanløse, DK;
Mikkel Jessing, København ç, DK;
Eman Mohamed Eldemenky, Wayne, NJ (US);
Bin Chen, East Windsor, NJ (US);
Yu Jiang, East Windsor, NJ (US);
Allen T. Hopper, Katonah, NY (US);
Assignee:
MINDIMMUNE THERAPEUTICS, INC., Kingston, RI (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/505 (2006.01); C07C 233/66 (2006.01); C07C 233/75 (2006.01); C07C 233/78 (2006.01); C07D 211/26 (2006.01); C07D 213/40 (2006.01); C07D 233/64 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 241/12 (2006.01); C07D 309/04 (2006.01); C07D 401/06 (2006.01); C07D 403/06 (2006.01); C07D 405/04 (2006.01); C07D 405/06 (2006.01); C07D 231/12 (2006.01); C07D 403/04 (2006.01); C07D 213/61 (2006.01); C07C 233/73 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); C07C 233/66 (2013.01); C07C 233/73 (2013.01); C07C 233/75 (2013.01); C07C 233/78 (2013.01); C07D 211/26 (2013.01); C07D 213/40 (2013.01); C07D 213/61 (2013.01); C07D 231/12 (2013.01); C07D 233/64 (2013.01); C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 241/12 (2013.01); C07D 309/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 405/04 (2013.01); C07D 405/06 (2013.01); C07C 2601/08 (2017.05);
Abstract
The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2Xreceptor, and their use in the treatment of epilepsy.